@article {Bian2020.03.21.20040691, author = {Huijie Bian and Zhao-Hui Zheng and Ding Wei and Zheng Zhang and Wen-Zhen Kang and Chun-Qiu Hao and Ke Dong and Wen Kang and Jie-Lai Xia and Jin-Lin Miao and Rong-Hua Xie and Bin Wang and Xiu-Xuan Sun and Xiang-Min Yang and Peng Lin and Jie-Jie Geng and Ke Wang and Hong-Yong Cui and Kui Zhang and Xiao-Chun Chen and Hao Tang and Hong Du and Na Yao and Shuang-Shuang Liu and Lin-Na Liu and Zhe Zhang and Zhao-Wei Gao and Gang Nan and Qing-Yi Wang and Jian-Qi Lian and Zhi-Nan Chen and Ping Zhu}, title = {Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial}, elocation-id = {2020.03.21.20040691}, year = {2020}, doi = {10.1101/2020.03.21.20040691}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background SARS-CoV-2 is a novel human coronavirus, there is no specific antiviral drugs. It has been proved that host-cell-expressed CD147 could bind spike protein of SARS-CoV-2 and involve in host cell invasion. Antibody against CD147 could block the infection of SARS-CoV-2. We aimed to assess the efficacy and safety of meplazumab, a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia.Methods All patients received recommended strategy from Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatments released by National Health Commission of China. Eligible patients were add-on administered 10 mg meplazumab intravenously at days 1, 2, and 5. Patients hospitalized in the same period were observed as concurrent control. The endpoints include virological clearance rate, case severity, chest radiographic, and laboratory test. This trial was approved by the Ethics Committee of Institution at the Tangdu hospital, and registered with ClinicalTrials.gov, NCT 04275245.Findings 17 patients were enrolled and assigned to meplazumab group between Feb 3, 2020 and Feb 10, 2020. 11 hospitalized patients served as concurrent control. Baseline characteristics were generally balanced across two groups. Compared to control group, meplazumab treatment significantly improved the discharged (p=0.005) and case severity (p=0.021) in patients. The time to virus negative in meplazumab group was reduced than that in control group (median 3, 95\%CI[1.5-4.5] vs. 13, [6.5-19.5]; p=0.045, HR=0.374, 95\%CI[0.143-0.978]). The percentages of patients recovered to the normal lymphocyte count and CRP concentration were also increased remarkably and rapidly in meplazumab group. No adverse effect was found in meplazumab-treated patients.Interpretation Meplazumab efficiently improved the recovery of patients with SARS-CoV-2 pneumonia with a favorable safety profile. Our results support to carry out a large-scale investigation of meplazumab as a treatment for COVID-19 pneumonia.Funding National Science and Technology Major Project.Competing Interest StatementPZ, ZNC, HB, and ZZ were the inventors of the patent Humanized Anti-Basigin Antibodies and the Use Thereof (PCT/CN2017/082713), and all of the above authors were not the applicant or patentee of the patent. PZ, ZNC, HB, DW, ZZ, and XMY were the inventors of patent Humanized Anti-Basigin Antibody for use of coronavirus disease 2019 (COVID-19) therapy (202010166717.9, China), and all of the above authors were not the applicant or patentee of the patent. Other authors declare no competing interests. Clinical TrialNCT04275245Funding StatementThis study was funded by the National Science and Technology Major Project (2019ZX09732-001). The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, PZ, upon reasonable request.}, URL = {https://www.medrxiv.org/content/early/2020/09/27/2020.03.21.20040691}, eprint = {https://www.medrxiv.org/content/early/2020/09/27/2020.03.21.20040691.full.pdf}, journal = {medRxiv} }